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Acute bacterial skin and skin structure infections are caused mainly by Gram-positive bacte-
ria  which are often treated with intravenous vancomycin, daptomycin, or linezolid, with
potential step down to oral linezolid for outpatients. Tedizolid phosphate 200 mg  once daily
treatment for six days demonstrated non-inferior efﬁcacy, with a favourable safety proﬁle,
compared with linezolid 600 mg twice daily treatment for 10 days in the Phase 3 ESTABLISH-
1  and -2 trials. The objective of the current post-hoc analysis of the integrated dataset of
ESTABLISH-1 and -2 was to evaluate the efﬁcacy and safety of tedizolid (N = 182) vs linezolid
(N  = 171) in patients of Latino origin enrolled into these trials. The baseline demographic
characteristics of Latino patients were similar between the two treatment groups. Tedizolid
demonstrated comparable efﬁcacy to linezolid at 48–72 h in the intent-to-treat popula-
tion  (tedizolid: 80.2% vs linezolid: 81.9%). Sustained clinical success rates were comparablebetween tedizolid- and linezolid-treated Latino patients at end-of-therapy (tedizolid: 86.8%
vs  linezolid: 88.9%). Tedizolid phosphate treatment was well tolerated by Latino patients
ion with lower abnormal platelet counts at end-of-therapy (tedizolid:in  the safety populat3.4% vs linezolid: 11.3%, p = 0.0120) and lower incidence of gastrointestinal adverse events
(tedizolid: 16.5% vs linezolid: 23.5%). Population pharmacokinetic analysis suggested that
∗ Corresponding author at: Hospital Civil de Guadalajara, Calle Hospital #278 S.H., Guadalajara, 44100 Jalisco, Mexico.
E-mail  address: orca0059@prodigy.net.mx (A. Ortiz-Covarrubias).
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estimated tedizolid exposure measures in Latino patients vs non-Latino patients were sim-
ilar. These ﬁndings demonstrate that tedizolid phosphate 200 mg, once daily treatment for
six  days was efﬁcacious and well tolerated by patients of Latino origin, without warranting
dose adjustment.
© 2016 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND
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ram-positive bacteria, including methicillin-resistant
taphylococcus aureus (MRSA), are commonly associated with
kin and skin structure infections (SSSIs), bacteraemia and
osocomial pneumonia.1–3 Infections due to MRSA may
e associated with morbidity and mortality, particularly
n the elderly.3 MRSA-related infections are an increasing
roblem in Latin America,4–6 both in the healthcare envi-
onment and in the community. The epidemiology of MRSA
s constantly changing; both hospital-acquired (HA) and
ommunity-acquired (CA) MRSA circulating clones and their
ntibiotic resistance proﬁles vary considerably throughout
egions and countries.7 In 2003, the ﬁrst outbreak of infections
nvolving CA-MRSA strains in Latin America was described
n Uruguay and was caused by the Southwest Paciﬁc (SWP)
lone/sequence type (ST)-30/SCCmec  IVc.8 Furthermore, other
lones of CA-MRSA have been isolated in Brazil,9 Argentina,10
olombia, Ecuador, Venezuela,11 Mexico,12 and Chile.13 A
onsiderable amount of CA-MRSA has also been found among
osocomial isolates, at least in Colombia and Uruguay.14,15
Vancomycin, teicoplanin, daptomycin, tigecycline, line-
olid, clindamycin, and ceftaroline are commercially available
s parenteral intravenous agents for MRSA infections in many
ountries in Latin America.16 Despite the broad range of anti-
RSA antibiotics, initial empirical therapy is inappropriate in
 large number of patients leading to treatment failures,17
ncreased healthcare costs,18 and potentially increasing resis-
ance levels.19
Tedizolid phosphate is a novel oxazolidinone antibiotic20
ith at least 4-times higher potency than linezolid against
ram-positive bacteria including MRSA, vancomycin-
esistant enterococci (VRE), linezolid-resistant cfr+ S. aureus,
nd Streptococcus pyogenes.21,22 Tedizolid phosphate is con-
erted in vivo by non-speciﬁc phosphatases to its active
oiety tedizolid (TZD).23 Two pivotal randomised, double-
lind, double-dummy, multicentre, controlled, Phase 3
linical trials (ESTABLISH-1 and ESTABLISH-2) conducted in
atients with acute bacterial skin and skin structure infec-
ions (ABSSSI; i.e. cellulitis/erysipelas, wound infection and
ajor cutaneous abscess)24,25 demonstrated that tedizolid
hosphate, 200 mg,  once daily (QD) treatment for six days
as non-inferior to linezolid (LZD), 600 mg,  twice daily (BID)
reatment for 10 days.26–28 In addition, TZD had an improved
olerability and safety proﬁle compared with LZD, particularly
n terms of gastrointestinal (GI) adverse events (AEs) and
aematological parameters.26–28
Interethnic pharmacokinetic (PK) differences exist for cer-
ain antibacterial agents potentially inﬂuencing the efﬁcacylicense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
and safety of the antibiotic drug in patients.29 For example,
ciproﬂoxacin metabolism in Brazilian subjects differs from
that in other ethnic populations, while tigecycline clearance in
young healthy Afro-American subjects is higher than in Cau-
casian subjects.29 Furthermore, both intrinsic (e.g. genetics,
body size and fat distribution) and extrinsic ethnic factors may
inﬂuence the effects of an investigational drug via altered PK
and pharmacodynamics.30–32
The objectives of the current post-hoc analysis were to
evaluate the efﬁcacy and safety of TZD vs LZD for the treat-
ment of ABSSSI in patients of Latino origin enrolled into the
Phase 3 ESTABLISH studies. Furthermore, the TZD PK proﬁle of
these patients was evaluated based on population PK analysis.
Methods
Study  design  and  treatments
Both ESTABLISH-1 (NCT01170221) and ESTABLISH-2
(NCT01421511) were randomised, multicentre, double-blind,
double-dummy, active-controlled Phase 3 studies comparing
tedizolid phosphate 200 mg  QD (6-day course followed by 4-
day placebo treatment) vs LZD 600 mg  BID (10-day treatment)
for the treatment of patients with ABSSSIs. Patients enrolled
into ESTABLISH-1 received exclusively oral (PO) therapy,26
while patients in ESTABLISH-2 received intravenous (IV)
therapy with an optional switch to PO therapy when certain
criteria were met.27 The integrated dataset of ESTABLISH-1
and ESTABLISH-2 trials was analysed and reported by Shorr
et al.28
Ethical  approval
No ethical approval of this post-hoc analysis was required.
The ESTABLISH-1 and ESTABLISH-2 studies were conducted in
accordance with the 2008 Declaration of Helsinki and all rele-
vant international, European Union, national, and local rules
and legislation. Institutional review board or ethics commit-
tee approval was obtained at each participating centre and all
participants provided written informed consent. A data and
safety monitoring board reviewed safety data during the con-
duct of the study.26,27
Enrolment  criteria
Patients (aged ≥18 years old in ESTABLISH-1 and ≥12 years
old in ESTABLISH-2) were enrolled in both trials if they had an
ABSSSI (cellulitis/erysipelas, wound infection, or major cuta-
neous abscess) with a minimum lesion surface area of 75 cm2;
i s . 2 0186  b r a z j i n f e c t d 
wound infections and abscesses also required the lesion to
extend ≥5 cm from the margin of the wound or abscess. In
addition, patients had at least one local and one systemic
sign of infection, and a suspected/documented Gram-positive
pathogen at the site of infection.26,27 The institutional review
board or equivalent at each study centre approved the trials
and all patients provided written informed consent.26,27 Exclu-
sion criteria were previously described by Prokocimer et al.26
and Moran  et al.27
Demographic data, disease characteristics, co-
medications, comorbidities, race and ethnic origin (Latino
or non-Latino), primary cause of ABSSSI, digital photograph
of the lesion, lesion size, vital signs, and microbiological
specimen information were recorded on case report forms.
Population  deﬁnitions
The intent-to-treat population (ITT analysis set) included
all randomised patients (including the Latino subpopulation)
who  were eligible based on the inclusion criteria outlined
above.26,27 The clinically evaluable population (CE) included
all patients in the ITT analysis set who (1) complied with the
study protocol with no major violations, and (2) completed the
clinical response outcome assessment at the end-of-therapy
(EOT) visit, and (3) had no concomitant systemic antibiotic
therapy or topical antibiotic from the ﬁrst infusion of study
drug through to the EOT visit that was potentially effective
against the baseline pathogen, except adjunctive aztreonam
and/or metronidazole in patients with wound infections.
Two CE populations were analysed: the CE-EOT population
included ITT patients who had a valid assessment at the 48-
to 72-h visit and at the EOT visit, and the CE-post-treatment
evaluation (PTE) population included ITT patients who had a
valid assessment at the PTE visit. The safety analysis popula-
tion was comprised of all randomised patients who received
at least one dose of the study drug and had a post-treatment
assessment.26,27
Efﬁcacy  parameters
The primary efﬁcacy endpoint was early clinical response
rate at the 48- to 72-h visit. The primary endpoint in the
integrated analysis was represented by ≥20% reduction in
lesion size compared with baseline.28 Secondary endpoints
included: programmatic and investigator-assessed clinical
success rates at EOT (Day 11), investigator-assessed sustained
clinical success rates at the PTE visit in the intent-to-treat (ITT)
population, and also in the CE population.28
Safety  parameters
Safety was assessed by collecting information on adverse
events based on System Organ Class and deﬁnitions were
given as coded in Medical Dictionary for Regulatory Activi-
ties (MedDRA) v13.1. Treatment-emergent AEs (TEAEs) were
deﬁned as those that occurred or worsened after the ﬁrst dose
of study drug. In addition, safety assessments included clini-
cal chemistry and haematology laboratory results, vital signs
and electrocardiograms, and physical examinations. 1 6;2  0(2):184–192
Laboratory  measurements
Blood samples were collected at randomisation, on Day 1, Day
3, Day 7, EOT (Day 11), and PTE visits for assessments of vari-
ous haematological, toxicology parameters (e.g. haemoglobin,
platelets, neutrophils, bilirubin, creatinine, alanine amino-
transferase (ALT), aspartate aminotransferase [AST]), and
clinical chemistry analysis.
Population  pharmacokinetic  analysis
In the ESTABLISH trials, patients’ baseline parameters (height,
body weight, body mass index [BMI], ideal body weight [IBW],
age, sex, calculated creatinine clearance based on Cockcroft-
Gault formula, and total bilirubin level) were collected, and
race and ethnicity (Latino vs non-Latino) were also recorded
on case report forms.
The ﬁnal PK model of TZD (a 2-compartment model
with sigmoidal absorption, absolute bioavailability, and linear
elimination), was used to estimate TZD exposure measures
for each patient based on measured concentrations and
statistically signiﬁcant predictors (IBW and total bilirubin),
including the area under the concentration–time curve at
0–24 h (AUC0–24 h), minimum drug concentration (Cmin), and
maximum drug concentration (Cmax) on Day 1 and at steady-
state.33 This post-hoc population PK analysis of TZD exposure
at steady state in Latino patients included summaries of the
mean value, standard deviation, median, and range. Boxplots
of TZD AUC0–24 h, Cmax and Cmin at steady state are also pre-
sented.
Statistical  analysis
This post-hoc analysis focused on a subpopulation of patients
of Latino origin. Data (i.e. efﬁcacy, safety) are expressed
as mean ± standard deviation (SD). Population PK data are
expressed as mean, SD and range, and data are graphically
shown as boxplots including median, 25th, 50th, and 75th
percentiles, and whiskers as 5th and 95th percentiles. Statis-
tical signiﬁcance was deﬁned by p < 0.05. Post-hoc statistical
analysis was descriptive in nature.
Results
Demographics  of  Latino  patients
In the integrated analysis of the ESTABLISH trials a total of
1333 patients were randomised and received study drug, 353 of
whom were Latinos (26.5%) in the ITT population (TZD N = 182;
LZD N = 171). Of the Latino patients, 85.6% were enrolled from
the US/Canada region, 13.3% from the ‘Other’ region, which
included Latin America (Argentina, Brazil, and Peru), Australia,
New Zealand, and South Africa, and only 1.1% from Europe.
The baseline demographic parameters and disease char-
acteristics of the enrolled Latino patients in ESTABLISH-1 and
ESTABLISH-2 were similar between the two treatment groups
(Table 1). The proportion of male patients in the TZD arm
(73.1%) was slightly higher than in the LZD arm (60.2%), most
patients being <65 years old. There was no difference in the
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Table 1 – Baseline demographic parameters and disease
characteristics for Latino patients.
Integrated ITT analysis set Tedizolid
(N = 182)
Linezolid
(N = 171)
Male patients, n (%) 133 (73.1) 103 (60.2)
Mean age (range), years 40.8 (18–86) 42.6 (19–84)
Age group, n (%)
<65 years 173 (95.1) 161 (94.2)
≥65 to ≤75 years 7 (3.8) 7 (4.1)
>75 years 2  (1.1) 3 (1.8)
Mean ± SD BMI,  kg/m2 29.7 ± 6.9 29.6 ± 6.1
Comorbidities, n (%)
Obesity 67 (36.8) 74 (43.3)
Diabetes mellitus 22 (12.1) 12 (7.0)
Hepatic impairment 1 (0.5) 0 (0.0)
Renal impairment 2 (1.1) 5 (2.9)
HIV positive 1 (0.5) 0 (0.0)
Hepatitis C virus positive 70 (38.5) 82 (48.0)
Current/recent IV drug use, n
(%)
82 (45.1) 91 (53.2)
ABSSSI type, n (%)
Cellulitis/erysipelas 66 (36.3) 67 (39.2)
Wound infection 61 (33.5) 57 (33.3)
Major cutaneous abscess 55 (30.2) 47 (27.5)
Anatomical location of ABSSSI, n (%)
Chest/Abdomen 14 (7.7) 10 (5.8)
Groin/Buttock/Back 32 (17.6) 30 (17.5)
Head/Neck 5 (2.7) 4 (2.3)
Lower extremity
(Foot/Leg/Knee)
77  (42.3) 72 (42.1)
Upper extremity
(Hand/Arm)
54  (29.7) 55 (32.2)
Disease characteristics
Lesion surface area,
mean (range), cm2
288.9 (22.5–1847.0) 295.7 (27.0–2397.0)
Prior ABSSSI lesion, n (%) 50 (27.5) 43 (25.1)
Concurrent secondary
cSSSI/ABSSSI lesion, n (%)
36 (19.8) 25 (14.6)
Temperature ≥38 ◦C
(fever), n (%)
21 (11.5) 16 (9.4)
SIRS, n (%) 27 (14.8) 20 (11.7)
Lymphadenopathy, n (%) 161 (88.5) 145 (84.8)
WBC ≥10,000 or
<4000 cells/mm3 n (%)
78 (42.9) 64 (37.4)
Immature neutrophils
>10%, n (%)
7  (3.8) 6 (3.5)
MRSA, n (%) 49 (26.9) 39 (22.8)
Bacteraemia, n (%) 2 (1.1) 4 (2.3)
Region of enrolment, n (%)
US/Canada 156 (85.7) 146 (85.4)
Europe 4 (2.2) 0 (0.0)
Othera 22 (12.1) 25 (14.6)
a Other: Latin America (Argentina, Brazil, and Peru), Australia, New
Zealand, and South Africa.
ABSSSI, acute bacterial skin and skin structure infection; BMI,
body mass index; cSSSI, complicated skin and skin structure
infection; HIV, human immunodeﬁciency virus; ITT, intent-to-
treat, IV, intravenous; MRSA, methicillin-resistant Staphylococcus
aureus; SD, standard deviation; SIRS, systemic inﬂammatory
response syndrome; US, United States; WBC, white blood cell.
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Fig. 1 – Proportion of Latino patients with clinical response
at 48–72 h and clinical success at end of therapy and
post-treatment evaluation visits (ITT analysis set). ITT:
intent-to-treat.
Table 2 – Clinical efﬁcacy of tedizolid vs linezolid in
Latino and non-Latino patients.
Tedizolid, %
(n/N)
Linezolid, %
(n/N)
Treatment
difference (95% CI)
Early clinical response rate (responders) at the 48- to 72-h visit
ITT population
Latino 80.2 (146/182) 81.9 (140/171) −1.65 (−9.88; 6.65)
Non-Latino 82.2 (396/482) 78.5 (391/498) 3.64 (−1.37; 8.55)
Clinical success rate at EOT
ITT population
Latino 86.8 (158/182) 88.9 (152/171) −2.08 (−9.04; 4.91)
Non-Latino 87.1 (420/482) 87.6 (436/498) −0.41 (−4.64; 3.77)
CE population
Latino 92.5 (148/160) 92.6 (150/162) −0.09 (−6.2; 5.93)
Non-Latino 91.3 (399/437) 94.5 (412/436) −3.19 (−6.71; 0.25)
Investigator assessment of clinical success rate at PTE
ITT population
Latino 85.2 (155/182) 86.0 (147/171) −0.80 (−7.77; 7.23)
Non-Latino 87.3 (421/482) 87.1 (434/498) 0.20 (−4.05; 4.37)
CE population
Latino 91.9 (148/161) 92.7 (140/151) −0.79 (−7.22; 5.27)
Non-Latino 94.1 (384/408) 96.8 (396/409) −2.7 (−5.78; 0.14)
CE, clinically evaluable; CI, conﬁdence interval; EOT, end-of-
therapy; ITT, intent-to-treat; PTE, post-treatment evaluation.BMI  of patients treated with TZD (29.7 ± 6.9 kg/m2) or LZD
(29.6 ± 6.1 kg/m2), respectively; on average, 40% of all Latino
patients were obese and 9.6% had diabetes mellitus (Table 1).
The proportion of patients enrolled with cellulitis, wound
infection or major abscess, and the mean lesion size were
similar between treatment groups (TZD: 288.9 cm2 vs LZD:
295.7 cm2) (Table 1). MRSA was the causative Gram-positive
pathogen in 26.9% of TZD-treated and 22.8% of LZD-treated
patients, respectively.
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Table 3 – Incidence of adverse events in the safety
population of Latino patients.a
Tedizolid
(N = 182)
n  (%)
Linezolid
(N = 170)
n (%)
A
Overall adverse events
Any treatment-emergent AE
(TEAE)
86  (47.3) 81 (47.6)
Drug-related TEAE 45 (24.7) 56 (32.9)
TEAE leading to
discontinuation of study drug
1  (0.5) 2 (1.2)
Serious TEAE 3 (1.6) 0 (0.0)
Drug-related serious TEAE 0 (0.0) 0 (0.0)
Any serious TEAE leading to
death
1  (0.5) 0 (0.0)
B
System organ class preferred term (≥2% TEAE)
Gastrointestinal disorders 30 (16.5) 40 (23.5)
Nausea 16 (8.8) 19 (11.2)
Diarrhoea 7 (3.8) 13 (7.6)
Vomiting 7 (3.8) 8 (4.7)
Constipation 4 (2.2) 4 (2.4)
Table 4 – Abnormal platelet counts (109/L) by timepoint
in Latino patients.
Abnormal platelet
counts (109/L) by
time points in the
Safety Analysis set
Tedizolid
(N  = 182)
Linezolid
(N = 170)
p-Value
Study Day 7–9,a N1 150 141
Below LLN, n (%) 9 (6.0) 7 (5.0) NS
Below 75% of LLN,
n (%)
3  (2.0) 0 (0) NS
Study Day 11–13,b N1 147 142
Below LLN, n (%) 5 (3.4) 16 (11.3) 0.012
Below 75% of LLN,
n (%)
0 (0) 4 (2.8) 0.057
Last dose of active
drug visit,c N1
157 144
Below LLN, n (%) 10 (6.4) 16 (11.1) NS
Below 75% of LLN,
n (%)
4  (2.5) 4 (2.8) NS
LLN, lower limit of normal; NS, not signiﬁcant; N1, number of
patients in safety analysis population with non-missing data at
baseline and the summarised visit.
a Day 7 (up to +2 days) visit by protocol.
b Day 11 (up to +2 days) visit by protocol.
LZD (11.1%) than TZD (6.4%) after the last dose of the activeAE, adverse event; TEAE, treatment-emergent adverse events.
a Data are reported by patients.
Efﬁcacy  of  tedizolid  and  linezolid  in  Latino  patients
The efﬁcacy of TZD was compared with LZD in the ITT popu-
lation. In patients with Latino ethnicity in the integrated data
of the ESTABLISH studies, comparable efﬁcacy results were
demonstrated between six days of TZD and 10 days of LZD
(Fig. 1). Similarly to the overall population, in Latino patients
tedizolid phosphate treatment demonstrated comparable efﬁ-
cacy with LZD treatment at the 48- to 72-h visit in the ITT
population (TZD: 80.2% vs LZD: 81.9%; point difference: −1.65;
95% conﬁdence interval (CI): −9.88; 6.65) (Table 2, Fig. 1).
At EOT, similar clinical success rates were found in the
ITT (86.8% in TZD vs 88.9% in LZD; point difference: −2.08;
95% CI: −9.04; 4.91) and CE (92.5% in TZD vs 92.6% in LZD;
point difference: −0.1; 95% CI: −6.2; 5.93) populations (Table 2).
Furthermore, investigator-assessed clinical success rates were
comparable in patients treated with TZD vs LZD at the PTE visit
in the ITT and CE populations (Table 2).
Safety  and  tolerability  of  tedizolid  and  linezolid  in  Latino
patients
Among Latino patients in the safety analysis population, 182
TZD-treated patients and 170 LZD-treated patients received
at least one dose of the study drug and were eligible for
safety analysis. In the Latino population, overall treatment-
emergent adverse events (TEAE) rates were comparable in both
TZD- (47.3%) and LZD- (47.6%) treated patients (Table 3A). The
investigator-assessed rate of drug-related AEs was lower in the
TZD treatment arm (45/182 patients, 24.7%) compared with
the LZD treatment arm (56/170 patients, 32.9%), respectively.
These results are similar to the overall integrated safety popu-
lation (TZD: 148/662 patients [22.4%] vs LZD: 185/662 patients
[27.9%], respectively).c Visit closest to the last dose of the active study drug (patients
could have discontinued study drug treatment before Day 10).
Similar to the overall population, in Latino patients the
most commonly reported AEs were GI related; however,
the incidence of GI-related AEs was lower in TZD-treated
patients compared with LZD-treated patients (16.5% vs 23.5%,
respectively). Among GI adverse events, lower incidences of
nausea, diarrhoea, vomiting were reported in TZD-treated
Latino patients compared with LZD-treated Latino patients
(Table 3B).
Rates of TEAEs leading to discontinuation of study drug
were low and similar with TZD (0.5%) and LZD (1.2%) treat-
ments in Latino patients (Table 3A). In this analysis, rates of
serious TEAEs were also similar between the two treatment
groups (TZD: 3 out of 182 patients [1.6%] and LZD: 0 out of 170
patients [0%], respectively) (Table 3A). No serious drug-related
TEAEs occurred with either TZD or LZD, and only one TEAE
leading to death was observed (in the TZD group) which was
unrelated to study drug (Table 3A).
Laboratory  results
Platelets
Among Latino patients, the proportion of patients with
reduced platelet counts was similar between the two treat-
ment arms at Day 7–9. Abnormal platelet count (i.e. below
lower limit of normal [LLN]) was observed at approximately
three-fold higher incidence in patients treated with LZD
(11.3%) than TZD (3.4%) at Day 11–13 (Table 4); similarly, a
higher incidence of abnormal platelet count was seen withstudy drug, respectively.
The proportion of patients with substantially abnormal
platelet count was very low in both treatment arms at all time
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Table 5 – Summary statistics of tedizolid exposure
measures from Latino and non-Latino patients.
Exposure
measures of
tedizolid
Latino
N  = 179a
Non-Latino
N = 468
Overall
N = 647
AUC(0–24),ss
(ng·h/mL)
Mean
(SD)
21,919.46
(5708.09)
22,715.61
(6407.01)
22,495.35
(6227.37)
Range  6570.1;
39,344.0
8885.9;
49,861.0
6570.1;
49,861.0
Cmax,ss (ng/mL)
Mean
(SD)
1859.94
(509.76)
1984.91
(541.81)
1950.33
(535.67)
Range 544.9;
3244.3
520.8;
4518.7
520.8;
4518.7
Cmin,ss (ng/mL)
Mean
(SD)
357.93
(210.30)
359.70
(215.19)
359.21
(213.69)
Range 7.8;  1170.4 15.3; 1438.9 7.8; 1438.9
AUC(0–24),ss, area under the concentration curve at steady state;
Cmax,ss, maximum concentration at steady state; Cmin,ss, minimum
concentration at steady state; SD, standard deviation.
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Fig. 2 – Boxplots of tedizolid AUC0–24, Cmax, Cmin at
steady-state in Latino and non-Latino patients. Boxes are
25th, 50th, and 75th percentiles with median as horizontal
line; whiskers are 5th and 95th percentiles. Asterisks show
data points outside of this range. The number of subjects is
provided above each box. (A) AUC(0–24),ss area under the
concentration curve at steady state. (B) Cmax,ss, maximum
concentration at steady state. (C) Cmin,ss, minimum
concentration at steady state.a Number of patients with evaluable pharmacokinetic measures.
oints indicating the lack of clinically signiﬁcant thrombocy-
openia (Table 4).
ther  laboratory  results
o clinically meaningful changes were observed in
aemoglobin, absolute neutrophil or leucocyte counts in
ither the TZD or LZD treatment arms in Latino patients (data
ot shown).
opulation  PK  results
n the population PK analysis, no clinically meaningful covari-
te effects on TZD PK were found, although the ﬁnal model did
nclude the statistically signiﬁcant covariates IBW and total
ilirubin. Based on the model, summary measures of TZD
xposure parameters were generated for Latino patients and
ompared with those of non-Latino patients.
In the population used for the PK modelling, there were
o clinically meaningful differences between Latino (N = 182)
nd non-Latino (N = 482) ITT populations with regard to
aseline demographic or laboratory parameters. Among the
atino patients, there were more  males (73.1% vs 61.4%,
espectively) and patients aged ≤65 years (95.1% vs 86.9%,
espectively) compared with non-Latino patients. Latino
atients had a slightly higher, but not statistically sig-
iﬁcantly, BMI  (29.7 ± 6.9 kg/m2) than non-Latino patients
27.7 ± 6.6 kg/m2).
PK parameters expressing TZD exposure in Latino
atients (N = 179) were compared with those of non-
atino patients (N = 468). There were no apparent dif-
erences at steady state between Latino and non-Latino
atients (Table 5) in TZD AUC0–24 h (21,919.5 ± 5708.1 ng × h/mL
s 22,715.6 ± 6407.0 ng × h/mL, respectively; Fig. 2A), Cmax
1859.9 ± 509.8 ng/mL vs 1984.9 ± 541.8 ng/mL, respectively;
ig. 2B) and Cmin (357.9 ± 210.3 ng/mL vs 359.7 ± 215.2 ng/mL,
espectively; Fig. 2C).Discussion
This post-hoc analysis of the integrated dataset of ESTABLISH-
1 and ESTABLISH-2 was performed to compare the efﬁcacy of
tedizolid phosphate 200 mg  once daily IV/PO 6-day treatment
with that of LZD 600 mg  twice daily IV/PO 10-day treatment
in Latino patients with ABSSSIs. Furthermore, this analysis
aimed to assess the safety proﬁle of TZD in Latino patients
and to compare estimates of TZD exposure in Latino and
non-Latino patients. Based on the primary endpoint criteria,
the results of the analysis showed comparable early clini-
cal response rates with TZD and LZD treatments in Latino
i s . 2 0190  b r a z j i n f e c t d 
patients at the 48- to 72-h visit. Similar proportions of patients
in the two treatment arms had sustained clinical success
at the EOT and PTE visits. TZD was well tolerated in Latino
patients with a lower incidence of GI AEs compared with LZD,
similar to that seen with TZD in both non-Latino patients and
the overall population. The incidence of thrombocytopenia
was also lower for TZD than for LZD at Day 11–13, though the
incidences were similar in the two groups at Day 7–9 and after
the last dose of the active drug.
These results are in accordance with those in the overall
integrated ITT population of ESTABLISH-1 and ESTABLISH-
2.26–28,34 In the overall ITT population at the 48- to 72-h
visit, approximately 80% of TZD- and LZD-treated patients
demonstrated at least a 20% reduction in lesion size. A sig-
niﬁcant advantage was also seen with TZD treatment with
regard to GI AEs28 and haematological changes in the overall
population.26–28,34 Although similar trends were observed in
the Latino subpopulation, signiﬁcance was not demonstrated
which was probably due to the lower number of patients in
each arm. Nevertheless, the lower incidence of GI AEs and the
lower risk of thrombocytopenia are favourable safety aspects
of TZD treatment which might also apply to Latino patients.
The improved haematological effects of TZD vs LZD may be
the result of a smaller impact on mitochondria due to lower
overall drug exposure and trough concentration.35
It is known that LZD treatment for more  than 28 days
is associated with neurotoxicity.36,37 A 6-month daily LZD
exposure in rats, at 80 mg/kg/day dose which reproduces the
human daily exposure of 600 mg  BID, resulted in peripheral
(sciatic) neuropathy within three months and optic nerve neu-
ropathy within six months.37 On the contrary, rats exposed
to daily administration of TZD for nine months, at a dose
providing 8-fold higher exposure than the approved therapeu-
tic dose, showed no signs of neurotoxicity during this time
period.38 The lower risk of toxicity was also demonstrated in
the ESTABLISH studies by the signiﬁcantly lower incidence of
GI AEs during the ﬁrst six days of therapy when both drugs
were administered, and not only over the entire observa-
tion period.26–28 No unexpected safety signal was observed
in the Latino subpopulation or the full study safety popula-
tion. TZD was well tolerated in both populations with similar
incidences of TEAEs and reduced rate of drug-related AEs
compared with those Latino patients who were treated with
LZD.
LZD is an approved oral anti-MRSA drug in Latin American
countries with the advantages of 100% oral bioavailability and
no interethnic differences in PK properties.29 Previous Phase
1 studies have demonstrated high oral bioavailability of tedi-
zolid (>90%).23 The population PK analyses revealed that there
was no difference between Latino and non-Latino patients in
the estimates of TZD exposure measures. The demographic
parameters and the population PK model indicated that there
were no clinically signiﬁcant covariates, including race33; this
suggests that the 200 mg  dose of tedizolid phosphate was
appropriate for Latino patients for the treatment of ABSSSI
and no dose adjustment is necessary for patients of this eth-
nicity. Previously, no statistical inﬂuence of sex, age, race,
ethnicity, body weight, BMI, ALT, AST, or creatinine clearance
was found on TZD population PK parameters.33 IBW and total
bilirubin were found to be statistically signiﬁcant covariates 1 6;2  0(2):184–192
for observed variability of PK parameters; however, neither of
these effects were determined to be clinically relevant.33
As endorsed by current antimicrobial stewardship rec-
ommendations, shorter courses of treatment are advocated
in order to minimise the risk of antimicrobial resistance
development, optimise the safety proﬁle and improve patient
compliance with treatment. TZD demonstrates at least 4-
times greater potency than LZD against a wide range of
Gram-positive pathogens, including MRSA and VRE.21,22 The
greater potency was the result of modiﬁcation of the core
structure in three different ways.20 These modiﬁcations and
the greater potency led to the hypothesis that TZD may be
efﬁcacious at a lower dose and in shorter treatment duration
compared with LZD. This hypothesis was demonstrated in a
Phase 2 study where the lowest dose tested (200 mg  QD) proved
as efﬁcacious as higher doses in patients with ABSSSI,39 and
later conﬁrmed in the two pivotal Phase 3 studies. Based on
these results, tedizolid phosphate is now approved at a dose
of 200 mg  as a once daily IV and/or oral therapy for the man-
agement of patients with ABSSSIs in the US,40 Europe, Canada,
Singapore, Kuwait, and Chile, with a short treatment duration
of six days.40
High bacteriological eradication rate and consequently
high clinical cure rate were demonstrated in patients at
the PTE visit in the overall population. Susceptibility test-
ing to TZD and LZD showed that all MRSA strains isolated
in the trials were susceptible to TZD according to the cur-
rent FDA and EU breakpoints [Susceptible: ≤0.5 g/mL].26–28
Bacteriological results were not obtained for Latino patients;
however, it is expected that TZD would be efﬁcacious against
Gram-positive pathogens causing infection in Latino patients
enrolled into the studies. A recent surveillance study of nearly
7000 Gram-positive isolates (including approximately 4500 S.
aureus isolates) conducted globally demonstrated a high rate of
susceptibility to TZD and LZD with only 16 isolates (including
seven S. aureus,  ﬁve S. epidermidis, and four enterococci) being
resistant to LZD.22 However, some of these isolates remained
susceptible to TZD if they carried a plasmid encoding for Cfr
methylase only.22
One of the limitations of this analysis was that it was
a post-hoc subgroup analysis with lower patient numbers
per treatment group; therefore, the analysis was not pow-
ered to demonstrate statistical difference between Latino and
non-Latino populations in efﬁcacy and safety parameters.
Consequently, further studies are required to strengthen the
clinical value of the efﬁcacy and safety ﬁndings and results of
the current analysis. An ongoing global Phase 3 clinical study
which compares the efﬁcacy and safety of TZD and LZD in
patients with nosocomial pneumonia will provide additional
information regarding the safety of TZD in Latino patients.
Ethnic factors have been shown to inﬂuence the safety
and efﬁcacy of several compounds; in fact, the FDA and
EMA have encouraged the presence of patients from dis-
tinct ethnicity and/or race in clinical trials of drugs under
development.30,31 It is hypothesised that inter-ethnic dif-
ferences in the PK of antibiotics depend on the ﬁrst-pass
metabolism and transport mechanisms because some agents
demonstrate relatively low bioavailability.29 These inter-
ethnic differences appear to be common, although their
clinical relevance must be investigated.29 The fact that the
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harmacokinetic/pharmacodynamic properties of TZD were
ot affected by ethnicity (or race) might explain the similar
ndings in efﬁcacy and safety of TZD between Latino and
on-Latino patients enrolled in the ESTABLISH trials.
onclusion
n conclusion, the results of the current analysis suggest that
ZD was efﬁcacious and well tolerated in the management
f Latino patients with ABSSSIs. The population PK analysis
f patients enrolled into ESTABLISH-1 and ETABLISH-2 sug-
est that no dose adjustment is needed for Latino patients for
he treatment of ABSSSI. Furthermore, these ﬁndings indicate
hat TZD may be an appropriate choice of treatment for Latino
atients with ABSSSIs who  are either hospitalised or outpa-
ients due to the high potency and high oral bioavailability
f the agent; this is also supported by the favourable safety
roﬁle of TZD demonstrated in the current study. However,
rescription of TZD (or linezolid) for Latino patients should
e considered according to the approved Summary of Product
haracteristics and local guidelines.
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